ArticleFrontiers in neurology
Dopaminergic medication alters muscle synergy during sit-to-stand motion in Parkinson's disease.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Levodopa-induced alterations in vertical center of mass and muscle synergy structure during Parkinsonian gait.Experimental brain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder that impairs motor function, thereby influencing daily activities, including sit-to-stand (STS) motion. Dopaminergic medication improves motor symptoms; however, its effects on neuromuscular control during STS motion remain unclear. This study investigated the effects of dopaminergic medication on muscle synergy and kinematic performance during STS motion in patients with PD. Methods: Fourteen patients with PD performed STS motion in the OFF and ON medication states. Surface EMG data from eight trunk and lower limb muscles and kinematic data of the center of mass (COM) trajectory were recorded. Muscle synergies were extracted using non-negative matrix factorization to assess temporal features and activation patterns. Kinematic features, including STS duration, time to seat-off, and COM displacement angle (initial to seat-off), were analyzed. Results: Dopaminergic medication significantly improved muscle synergy, achieving earlier initiation of the seat-off synergy and improved coordination between the propulsive and postural stabilization synergies. Neuromuscular improvement showed associations with changes in functional performance. Kinematic analysis revealed that the ON state was marked by shorter movement duration, reduced seat-off time, and a downward COM trajectory. These findings indicated that dopaminergic medication improves muscle synergy activation timing to enhance movement efficiency. Conclusion: These findings suggest that dopaminergic medication enhances the temporal precision of neuromuscular coordination and resolves the dysfunctional compensatory strategies during STS motion. These results provide novel insights into how dopamine modulates motor control in PD, with implications for clinical assessment and rehabilitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.